Lapuleucel-T - Bausch Health Companies
Alternative Names: APC 8024; BA 7072; Cancer vaccine HER-2/neu - Dendreon; DN24-02; HER-2/neu cancer vaccine - Dendreon; Neuvenge™Latest Information Update: 05 Nov 2023
At a glance
- Originator Dendreon Corporation
- Class Cancer vaccines; Dendritic cell vaccines; Immunotherapies
- Mechanism of Action ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Urogenital cancer
- No development reported Colorectal cancer; HER2 positive breast cancer; Ovarian cancer
Most Recent Events
- 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
- 04 Nov 2017 No recent reports of development identified for phase-I development in Colorectal-cancer in USA (IV, Infusion)
- 04 Nov 2017 No recent reports of development identified for phase-I development in HER2-positive-breast cancer in USA (IV, Infusion)